Patent US5089479A successfully refreshed from Google Patents.
US5089479A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
Assignee: United States Department of Health and Human Services
•
Filing: 1988-11-28
•
Granted: 1992-02-18
•
Expires: 2008-11-28
Abstract
Abstract The invention is a carbohydrate receptor for Mycoplasma pneumoniae and Mycoplasma hominus and its use to detect mycoplasma in biological fluids and diseased tissue and cells. The receptor can be included in a composition having a pharmaceutically acceptable carrier. Methods are provided for purifying, detecting, or removing mycoplasma from diseased tissue or fluids. The receptor includes sulfatides, dextran sulfate, sialyloligosaccharides, and mixtures thereof.
Inventors
- 👤 Howard C. Krivan
- 👤 Victor Ginsburg
- 👤 David D. Roberts
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 16:21
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7004; A61P; A61P13/00; A61P13/02; A61P15/00; A61P31/00; A61P31/04; C; C12; C12Q; C12Q1/00; C12Q1/02; C12Q1/24; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56911; G01N33/56933; Y; Y10; Y10S; Y10S435/00; Y10S435/80; Y10S435/8215; Y10S435/822; Y10S435/87
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
30 words
A receptor which is capable of binding to Mycoplasma hominus and Mycoplsma pneumoniae comprising a compound selected from the group consisting of compounds containing the structure SO 3 - -Galβ1-1Ceramide.
Claim 2
Dependent Claim
30 words
A receptor which is capable of binding to Mycoplasma hominus and Mycoplsma pneumoniae comprising a compound selected from the group consisting of compounds containing the structure SO 3 - -Galβ1-1Ceramide.
Claim 3
Dependent Claim
26 words
A receptor according to claim 1 wherein said compound containing the structure SO 3 - -Galβ1-1Ceramide is selected from the group consisting of sulfatides and sialyloligosaccharides.
Claim 4
Dependent Claim
15 words
A pharmaceutical composition comprising the receptor according to claim 1 in a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
15 words
The composition according to claim 3 wherein said pharmaceutically acceptable carrier is soluble in water.
Claim 6
Dependent Claim
15 words
The composition according to claim 3 wherein said pharmaceutically acceptable carrier is insoluble in water.
Claim 7
Dependent Claim
57 words
A method for removing a pathogen selected from the group consisting of Mycoplasma hominus and Mycoplasma pneumoniae from a sample, comprising contacting said sample with a receptor according to claim 1, incubating said sample with said receptor for a sufficient period of time to bind said sample to said receptor, and removing said receptor from said sample.
Claim 8
Dependent Claim
16 words
The method according to claim 6 wherein said receptor is carried on a solid, water-insoluble carrier.
Claim 9
Dependent Claim
36 words
A method for treating a patient infected with a pathogen selected from the group consisting of Mycoplasma hominus and Mycoplasma pneumoniae comprising administering to said patient an effective amount of a composition according to claim 3.
Claim 10
Independent Claim
46 words
A method for detecting a pathogen selected from the group consisting of Mycoplasma pneumoniae and Mycoplasma hominus comprising: immobilizing fetuin onto a suitable carrier; contacting a sample to be analyzed with the immobilized fetuin; and detecting the presence of the pathogen using an enzyme-dextran sulfate conjugate.
Claim 11
Independent Claim
46 words
A method for detecting a pathogen selected from the group consisting of Mycoplasma pneumoniae and Mycoplasma hominus comprising: immobilizing fetuin onto a suitable carrier; contacting a sample to be analyzed with the immobilized fetuin; and detecting the presence of the pathogen using an enzyme-dextran sulfate conjugate.
Claim 12
Dependent Claim
37 words
A method of preventing infection in a host by a pathogen selected from the group consisting of Mycoplasma pneumoniae and Mycoplasma hominus comprising administering to a host an effective amount of a composition according to claim 3.
Claim 13
Dependent Claim
35 words
A method for treating diseased tissues which is infected with a pathogen selected from the group consisting of Mycoplasma pneumoniae and Mycoplasma hominus comprising contacting said diseased tissues with a composition according to claim 3.
References Cited (Backward Citations)
US3668075A
Cited
US4543328A
Cited
US4330622A
Cited
US4657849A
Cited
US4632902A
Cited
US4725557A
Cited
US4652518A
Cited
US4590181A
Cited
WO1986004064A1
Cited
US4863852A
Cited
US4840941A
Cited
US4752565A
Cited
EP0270317A2
Cited
US4869826A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-02-17 | 1995-08-19 | 1996-02-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-02-17 | 1999-08-19 | 2000-02-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-02-17 | 2003-08-19 | 2004-02-18 | $7700.00 | Window Closed / Lapsed |